Cybin Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Actualización de narrativa • Jul 24

HELP: Phase 3 Depression Readout And Cash Raise Will Drive Repricing

Analysts have reduced their price target on Cybin to reflect a lower fair value estimate of about $37.57. This adjustment is offset by expectations for very large future revenue growth, supported by a reduced future P/E assumption and only modest changes to profit margin and discount rate inputs.

Seeking Alpha • Jul 12

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

Summary I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP’s lead asset HLP003, an oral deuterated psilocin analog for adjunctive MDD, shows compelling Phase 2 efficacy, FDA Breakthrough Therapy Designation, and a differentiated clinical profile. Current valuation (~$269M EV, ~$207M pro forma cash) under-credits the probability-weighted value of HLP003, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds. Risks include functional unblinding, commercial launch hurdles, and potential dilution, but cash runway appears sufficient for near-term catalysts and positive data could drive a material re-rating. Read the full article on Seeking Alpha

Actualización de narrativa • Jul 10

HELP: Sector Depression Trial Milestones Will Shape This Psychedelic Undervaluation View

Analysts have reduced their price target for Cybin to reflect a revised fair value estimate of about $70.05, citing updated views on long term revenue potential, profit margins, and an adjusted future P/E outlook informed by recent psychedelic sector research on comparable late stage drug developers. Analyst Commentary Recent sector research on late stage psychedelic drug developers is shaping how bullish analysts think about Cybin, especially when they compare it with peers working on deuterated psilocin and similar compounds.

Actualización de narrativa • Jun 26

HELP: Policy Momentum On PTSD Treatments Will Drive Future Psychedelic Therapy Demand

Analysts have lowered their Cybin price targets to around $7.78 from about $22.14, citing updated assumptions that include a somewhat higher discount rate, slightly softer long term profit margins, and a reduced but still very large future P/E multiple, partly offset by higher projected revenue growth. What’s in the News for Cybin Cybin completed a follow on equity offering of approximately $50.0 million, issuing 10,309,280 common shares at a price of $4.85 per share, with a stated discount of $0.291 per security.

Artículo de análisis • Jun 17

We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Nueva narrativa • Apr 05

Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside

Catalysts About Cybin Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?

Nueva narrativa • Mar 22

Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety

Nueva narrativa • Mar 05

Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption

Catalysts About Cybin Cybin is a clinical stage company developing psychedelic based treatments for major depressive disorder and generalized anxiety disorder. What are the underlying business or industry changes driving this perspective?

CEO

Cybin no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric So	Co-Founder	5.8yrs	US$6.84m	5.13% $ 29.5m
Paul Glavine	Co-Founder	no data	US$6.84m	5.07% $ 29.2m
Greg Cavers	Chief Financial Officer	5.8yrs	US$1.00m	0.14% $ 805.2k
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	5.8yrs	US$1.12m	0.18% $ 1.0m
George Tziras	Chief Business Officer	2.8yrs	US$843.49k	0.060% $ 346.8k
John Kanakis	Co-Founder	no data	US$1.19m	sin datos
Aaron Bartlone	Chief Operating Officer	3.1yrs	US$764.06k	0.28% $ 1.6m
Alex Nivorozhkin	Chief Scientific Officer	5.7yrs	sin datos	sin datos
Lori Challenger	Chief Compliance	4.8yrs	sin datos	sin datos
Sara Somerset	Chief Communications Officers	no data	sin datos	sin datos
Douglas Sommerville	Chief Pharmaceutical Strategist	no data	sin datos	sin datos
Allison House-Gecewicz	Senior Vice President of Clinical Operations	4.6yrs	sin datos	sin datos

5.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HELP es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric So	Co-Founder	5.8yrs	US$6.84m	5.13% $ 29.5m
Paul Glavine	Co-Founder	5.8yrs	US$6.84m	5.07% $ 29.2m
Robert S. Langer	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Theresa Firestone	Lead Independent Director	5yrs	US$286.56k	0.10% $ 578.2k
Freda Lewis-Hall	Director & Chair of Scientific Advisory Committee	less than a year	sin datos	0.16% $ 928.0k
Mark Lawson	Independent Director	5.8yrs	US$291.77k	0.21% $ 1.2m
Grant Froese	Independent Director	5.8yrs	US$271.58k	0.21% $ 1.2m
Stephen Brannan	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Andrew Cutler	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Eric Hoskins	Independent Director	5.8yrs	US$271.58k	0.21% $ 1.2m

5.4yrs

Permanencia media

64.5yo

Promedio de edad

Junta con experiencia: La junta directiva de HELP se considera experimentada (5.4 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/08/05 12:44
Precio de las acciones al final del día	2026/08/05 00:00
Beneficios	2026/03/31
Ingresos anuales	2026/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Cybin Inc. está cubierta por 15 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
James Molloy	Alliance Global Partners
David Martin	Bloom Burton & Co.
Sumant Satchidanand Kulkarni	Canaccord Genuity

Cybin Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Cybin Inc., Annual General Meeting, Sep 22, 2026

Chief Financial Officer recently sold US$431k worth of stock

Helus Pharma Announces Scientific Advisory Board Appointments

Helus Pharma Announces CEO Changes Effective April 20, 2026

Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026

Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026

Recent updates

HELP: Phase 3 Depression Readout And Cash Raise Will Drive Repricing

Cybin Inc., Annual General Meeting, Sep 22, 2026

Helus Pharma Completes Enrollment In APPROACH Phase 3 Pivotal Study Of HLP003 In Adjunctive Treatment Of Major Depressive Disorder

Chief Financial Officer recently sold US$431k worth of stock

Cybin Raises $50 Million in Public Offering to Advance Psychedelic Drug Development

Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside

HELP: Sector Depression Trial Milestones Will Shape This Psychedelic Undervaluation View

HELP: Policy Momentum On PTSD Treatments Will Drive Future Psychedelic Therapy Demand

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $50.000008 million.

Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress

We Think Cybin (NASDAQ:HELP) Needs To Drive Business Growth Carefully

Helus Pharma Announces Scientific Advisory Board Appointments

Helus Pharma Announces CEO Changes Effective April 20, 2026

Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026

Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside

Late Stage Psychedelic Therapies And Clinic Partnerships Will Reshape Treatment For Depression And Anxiety

Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Interventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Inc. to Report Q2, 2026 Results on Nov 13, 2025

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. Highlights Upcoming Clinical Milestones

Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Insider recently bought US$73k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Announces George Tziras Not Standing for Re-Election

New major risk - Financial position

Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New minor risk - Shareholder dilution

No longer forecast to breakeven

Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC

Cybin Inc., Annual General Meeting, Aug 18, 2025

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

New minor risk - Share price stability

Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

No longer forecast to breakeven

New minor risk - Share price stability

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought US$64k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting